Skip to content

Evolus EOLS Evolysse — Total net revenues

Other product segments

Jeuveau
$66.02M-3.0%
Service revenue
$390K-12.9%

Similar metrics at other companies

Ligand Pharmaceuticals logo
LGNDEvomela — Total revenue and income
$1.49M-31.5%
Sarepta Therapeutics, Inc. logo
SRPTElevidys — Revenue
$101.97M-72.8%
Evolent Health, Inc. logo
EVHEvolent Health Services Segment — Revenue
$496.25M+2.6%
HRO
HROWVEVYE — Revenue
$20.95M-2.6%
Esperion Therapeutics logo
ESPRProduct sales, net — Total Revenues
$43.4M+24.3%
Ardelyx logo
ARDXProduct sales, net — Total revenues
$93.37M+37.7%

Other financials

Income statement

See full
Revenue$73.1M+6.7%
Gross profit$48.9M+4.8%
Operating income-$6.8M+54.9%
Net income-$10.7M+43.5%
EPS (diluted)-$0.16+46.7%

Balance sheet

See full
Cash & equivalents$49.8M-26.7%
Total debt$164.9M-4.1%
Total equity-$28.8M-336%
Total assets$220.6M+3.4%

Cash flow

See full
Operating cash flow-$10.0M+36.3%
CapEx$415.0K+30.1%
Free cash flow-$10.4M+35.0%

Valuation

See full
Market cap$470.86M-21.3%
Enterprise value$585.97M-16.6%
P/S1.6×-0.6×

Profitability

See full
Gross margin66.1%-2.4pp
Operating margin-13.7%-1.9pp
Net margin-14.4%-3.3pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×
Current ratio-0.3×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Evolus’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolus's evolysse — total net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evolus's evolysse — total net revenues?
Evolus (EOLS) reported evolysse — total net revenues of $6.73M in Q1 2026.
What does evolysse — total net revenues mean?
This metric represents the total net revenue generated from the sale of the Evolysse product line, excluding any assessed taxes. It serves as a key indicator of the market adoption and commercial performance of this specific aesthetic product offering within the company's portfolio. Tracking this revenue stream allows investors to evaluate the growth trajectory and contribution of this segment to the company's overall financial health.